KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Net Income for 6 consecutive years, with -$108.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 39.56% year-over-year to -$108.1 million, compared with a TTM value of -$644.8 million through Dec 2025, down 39.06%, and an annual FY2025 reading of -$644.8 million, down 39.06% over the prior year.
  • Net Income was -$108.1 million for Q4 2025 at Recursion Pharmaceuticals, up from -$162.3 million in the prior quarter.
  • Across five years, Net Income topped out at -$30.5 million in Q1 2021 and bottomed at -$202.5 million in Q1 2025.
  • Average Net Income over 5 years is -$93.2 million, with a median of -$84.0 million recorded in 2023.
  • The sharpest move saw Net Income tumbled 153.94% in 2021, then soared 39.56% in 2025.
  • Year by year, Net Income stood at -$65.0 million in 2021, then increased by 6.12% to -$61.0 million in 2022, then tumbled by 52.5% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then soared by 39.56% to -$108.1 million in 2025.
  • Business Quant data shows Net Income for RXRX at -$108.1 million in Q4 2025, -$162.3 million in Q3 2025, and -$171.9 million in Q2 2025.